Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

Kevin L Winthrop¹, Michael E Weinblatt², Joan Bathon³, Gerd R Burmester⁴, Philip J Mease⁵, Leslie Crofford⁶, Vivian Bykerk⁷, Maxime Dougados⁸, James Todd Rosenbaum^{9

10}, Xavier Mariette¹¹, Joachim Sieper¹², Fritz Melchers¹³, Bruce N Cronstein¹⁴, Ferry C Breedveld¹⁵, Joachim Kalden¹⁶, Josef S Smolen¹⁷, Daniel Furst^{5

18

19}

Affiliations

¹ Oregon Health Sciences University, Portland, Oregon, USA winthrop@ohsu.edu.
² Brigham and Womens Hospital, Boston, Massachusetts, USA.
³ Columbia University, College of Physicians & Surgeons, New York City, New York, USA.
⁴ Charité University Hospital, Berlin, Germany.
⁵ Swedish Medical Center, University of Washington, Seattle, Washington, USA.
⁶ Vanderbilt University, Nashville, Tennessee, USA.
⁷ Hospital for Special Surgery, New York City, New York, USA.
⁸ Hôpital Cochin, Paris, France.
⁹ Oregon Health Sciences University, Portland, Oregon, USA.
¹⁰ Legacy Devers Eye Institute, Portland, Oregon, USA.
¹¹ Paris-Sud University, APHP Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
¹² Department of Gastroenterology, Infectious Diseases and Rheumatology, Campus Benjamin Franklin, Charité, Berlin, Germany.
¹³ Max Planck Institute for Infection Biology, Berlin, Germany.
¹⁴ NYU School of Medicine, New York City, New York, USA.
¹⁵ Leiden University Medical Center, Leiden, The Netherlands.
¹⁶ University of Erlangen, Erlangen, Germany.
¹⁷ Division of Rheumatology, Department of Medicine 3, Medical University of, Vienna, Vienna, Austria.
¹⁸ University of California, Los Angeles Medical Center, Los Angeles, CA, USA.
¹⁹ University of Florence, Florence, Italy.

PMID: 31662322
PMCID: PMC6937409
DOI: 10.1136/annrheumdis-2019-216151

Review

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

Kevin L Winthrop et al. Ann Rheum Dis. 2020 Jan.

. 2020 Jan;79(1):88-93.

doi: 10.1136/annrheumdis-2019-216151. Epub 2019 Oct 29.

Authors

Affiliations

¹ Oregon Health Sciences University, Portland, Oregon, USA winthrop@ohsu.edu.
² Brigham and Womens Hospital, Boston, Massachusetts, USA.
³ Columbia University, College of Physicians & Surgeons, New York City, New York, USA.
⁴ Charité University Hospital, Berlin, Germany.
⁵ Swedish Medical Center, University of Washington, Seattle, Washington, USA.
⁶ Vanderbilt University, Nashville, Tennessee, USA.
⁷ Hospital for Special Surgery, New York City, New York, USA.
⁸ Hôpital Cochin, Paris, France.
⁹ Oregon Health Sciences University, Portland, Oregon, USA.
¹⁰ Legacy Devers Eye Institute, Portland, Oregon, USA.
¹¹ Paris-Sud University, APHP Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin Bicêtre, France.
¹² Department of Gastroenterology, Infectious Diseases and Rheumatology, Campus Benjamin Franklin, Charité, Berlin, Germany.
¹³ Max Planck Institute for Infection Biology, Berlin, Germany.
¹⁴ NYU School of Medicine, New York City, New York, USA.
¹⁵ Leiden University Medical Center, Leiden, The Netherlands.
¹⁶ University of Erlangen, Erlangen, Germany.
¹⁷ Division of Rheumatology, Department of Medicine 3, Medical University of, Vienna, Vienna, Austria.
¹⁸ University of California, Los Angeles Medical Center, Los Angeles, CA, USA.
¹⁹ University of Florence, Florence, Italy.

PMID: 31662322
PMCID: PMC6937409
DOI: 10.1136/annrheumdis-2019-216151

Abstract

Objectives: To detail the greatest areas of unmet scientific and clinical needs in rheumatology.

Methods: The 21st annual international Advances in Targeted Therapies meeting brought together more than 100 leading basic scientists and clinical researchers in rheumatology, immunology, epidemiology, molecular biology and other specialties. During the meeting, breakout sessions were convened, consisting of 5 disease-specific groups with 20-30 experts assigned to each group based on expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus and other systemic autoimmune rheumatic diseases. In each group, experts were asked to identify unmet clinical and translational research needs in general and then to prioritise and detail the most important specific needs within each disease area.

Results: Overarching themes across all disease states included the need to innovate clinical trial design with emphasis on studying patients with refractory disease, the development of trials that take into account disease endotypes and patients with overlapping inflammatory diseases, the need to better understand the prevalence and incidence of inflammatory diseases in developing regions of the world and ultimately to develop therapies that can cure inflammatory autoimmune diseases.

Conclusions: Unmet needs for new therapies and trial designs, particularly for those with treatment refractory disease, remain a top priority in rheumatology.

Keywords: Sjögren’s syndrome; ankylosing spondylitis; inflammatory myopathies; psoriatic arthritis; rheumatoid arthritis; spondyloarthritis; systemic lupus erythematosus; systemic sclerosis; vasculitis.

PubMed Disclaimer

Conflict of interest statement

Competing interests: KLW reports personal fees from Pfizer, grants and personal fees from BMS, personal fees from AbbVie, personal fees from UCB, personal fees from Lilly, personal fees from Galapagos, personal fees from GSK, personal fees from Roche outside the submitted work. JB reports personal fees from AbbVie outside the submitted work. MD reports grants and personal fees from Pfizer, grants and personal fees from Abbvie, grants and personal fees from Lilly, grants and personal fees from Novartis, grants and personal fees from UCB, grants and personal fees from Merck, grants and personal fees from Roche, during the conduct of the study. JTR reports grants from Pfizer, personal fees from Abbvie, personal fees from Gilead, personal fees from Santen, personal fees from Roche, personal fees from Novartis, personal fees from UCB, personal fees from Corvus, personal fees from Horizon, personal fees from Celldex, personal fees from Eyevensys, personal fees from UpToDate, personal fees from Janssen outside the submitted work. XM reports personal fees from BMS, personal fees from GILEAD, personal fees from PFIZER, personal fees from SAMSUNG, personal fees from UCB outside the submitted work. BNC has multiple patents, none of which are relevant. In addition he has multiple grants from NIH. JSS reports grants and personal fees from AbbVie, personal fees from Amgen, personal fees from AstraZeneca, personal fees from Astro, personal fees from Bristol-Myers Squibb, personal fees from Celgene, personal fees from Celltrion, personal fees from ILTOO, grants and personal fees from Janssen, grants and personal fees from Lilly, personal fees from MSD, grants and personal fees from Novartis-Sandoz, personal fees from Novo-Nordisk, grants and personal fees from Roche, personal fees from Samsung Bioepis, personal fees from Sanofi, personal fees from UCB, grants and personal fees from Pfizer outside the submitted work. DF reports grant/research support from Actelion, grant/research support from Amgen, grant/research support from BMS, grant/research support from Corbus, grant/research support from Galapagos GSK, grant/research support from NIH, grant/research support from Novartis, grant/research support from Pfizer, grant/research support from Sanofi, grant/research support from Roche/Genentech, personal fees from Actelion, personal fees from Amgen, personal fees from BMS, personal fees from Corbus, personal fees from Galapagos, personal fees from Novartis, personal fees from Pfizer outside the submitted work.

References

1. Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013;72:ii2–34. 10.1136/annrheumdis-2013-203348 - DOI - PubMed
1. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 2016;68:1–26. 10.1002/art.39480 - DOI - PubMed
1. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960–77. 10.1136/annrheumdis-2016-210715 - DOI - PubMed
1. Gossec L, Smolen JS, Ramiro S, et al. European League against rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016;75:499–510. 10.1136/annrheumdis-2015-208337 - DOI - PubMed
1. Winthrop KL, Strand V, van der Heijde DM, et al. The unmet need in rheumatology: reports from the targeted therapies meeting 2016. Clin Exp Rheumatol 2016;34:69–76. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

Affiliations

Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Research Materials